Literature DB >> 23469340

Draft Genome Sequence of Enterococcus faecalis PC1.1, a Candidate Probiotic Strain Isolated from Human Feces.

Páraic O Cuív1, Eline S Klaassens, Wendy J Smith, Stanislas Mondot, A Scott Durkin, Derek M Harkins, Les Foster, Jamison McCorrison, Manolito Torralba, Karen E Nelson, Mark Morrison.   

Abstract

Enterococcus faecalis is commonly isolated from the gastrointestinal tract of healthy infants and adults, where it contributes to host health and well-being. We describe here the draft genome sequence of E. faecalis PC1.1, a candidate probiotic strain isolated from human feces.

Entities:  

Year:  2013        PMID: 23469340      PMCID: PMC3587934          DOI: 10.1128/genomeA.00160-12

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Enterococcus faecalis is a facultative anaerobic bacterium that is a primary colonizer of the infant gastrointestinal tract and is also prevalent in the adult gastrointestinal tract (1–3). E. faecalis is typically considered to be a beneficial gut bacterium that has been shown to be capable of modulating the activities of specific animal pathogens (4, 5) and the host immune response (6, 7); consequently, several strains have been applied as probiotics for the maintenance of a healthy gut and the treatment of gut diseases, including diarrhea, irritable bowel syndrome, and ulcerative colitis (8–10). Despite this, E. faecalis is now also widely recognized as a potential gut pathogen that is capable of compromising the epithelial barrier (11), inducing inflammation in mouse models of experimental colitis (12, 13) and causing chromosomal instability in colonic epithelial cells (14, 15). Key intraspecies variations with relevance to pathogenesis exist, and thus, we sought to elucidate further the genomic potential of an E. faecalis isolate from a healthy human gut and to assess its potential as a probiotic candidate. We describe here the draft genome sequence of E. faecalis PC1.1, isolated as part of the Australian Human Gut Microbiome Project. E. faecalis PC1.1 was isolated from a pooled fecal sample collected from healthy human subjects by plating aerobically on brain heart infusion (BHI) medium. Genomic DNA was prepared, and a 454 Life Sciences Genome Sequencer (GS) FLX system was used at the J. Craig Venter Institute (JCVI) to generate 2,753,924 bp of DNA sequence at 30× coverage. The individual sequence reads were assembled using the Newbler Assembler v2.3 to generate 79 contigs. The contig N50 was approximately 57.3 kb and the largest contig assembled was approximately 132.5 kb. Finally, the DNA sequences were annotated using the JCVI prokaryotic annotation pipeline. The draft genome has a G+C content of 37.6% and contains 2,673 genes, with 2,619 protein-coding genes and 54 structural RNAs. As anticipated, the annotated genome of E. faecalis PC1.1 revealed the presence of factors relevant to the colonization of and persistence in the human gut, including protein orthologs with putative roles in mediating adhesion to host structural factors, including collagen, fibronectin, and fibrinogen. In addition, we identified a putative lectin with a suspected role in mediating adhesion to host structural glycans and also several proteins with likely roles in harvesting host glycans. The E. faecalis PC1.1 genome encodes a putative gelatinase and serine proteinase; however, it does not appear to encode an enterococcal surface protein or enterococcal cytolysin, which have been shown previously to be important for virulence. This preliminary study provides insight into the genomic factors that contribute to the colonization of and persistence in the gut. Nontoxigenic Clostridium difficile can effectively colonize the gut of hamsters and humans and prevent colonization by toxigenic C. difficile strains (reviewed in reference 16); further studies will be necessary to determine the probiotic potential of E. faecalis PC1.1, including its ability to similarly prevent colonization and/or modulate the activities of pathogenic microbes and to productively influence the immune response.

Nucleotide sequence accession numbers.

This Whole Genome Shotgun project has been deposited at DDBJ/EMBL/GenBank under the accession no. ADKN00000000. The version described here is the first version, ADKN01000000.
  16 in total

1.  Streptococcus faecalis, a bacterial isolate which protects young chickens from enteric invasion by Salmonellae.

Authors:  A S Soerjadi; A B Lloyd; R B Cumming
Journal:  Aust Vet J       Date:  1978-11       Impact factor: 1.281

Review 2.  Clostridium difficile infection prevention: biotherapeutics, immunologics, and vaccines.

Authors:  Dale N Gerding
Journal:  Discov Med       Date:  2012-01       Impact factor: 2.970

3.  Extracellular superoxide production by Enterococcus faecalis promotes chromosomal instability in mammalian cells.

Authors:  Xingmin Wang; Mark M Huycke
Journal:  Gastroenterology       Date:  2006-11-29       Impact factor: 22.682

4.  Enterococcus faecalis from newborn babies regulate endogenous PPARgamma activity and IL-10 levels in colonic epithelial cells.

Authors:  Alexandra Are; Linda Aronsson; Shugui Wang; Gediminas Greicius; Yuan Kun Lee; Jan-Ake Gustafsson; Sven Pettersson; Velmurugesan Arulampalam
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-30       Impact factor: 11.205

5.  Characterization of functional, safety, and probiotic properties of Enterococcus faecalis UGRA10, a new AS-48-producer strain.

Authors:  R Cebrián; A Baños; E Valdivia; R Pérez-Pulido; M Martínez-Bueno; M Maqueda
Journal:  Food Microbiol       Date:  2011-12-13       Impact factor: 5.516

6.  Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria.

Authors:  Sandra C Kim; Susan L Tonkonogy; Carol A Albright; Julia Tsang; Edward J Balish; Jonathon Braun; Mark M Huycke; R Balfour Sartor
Journal:  Gastroenterology       Date:  2005-04       Impact factor: 22.682

7.  Carriage of group D streptococci in the human bowel.

Authors:  C J Noble
Journal:  J Clin Pathol       Date:  1978-12       Impact factor: 3.411

8.  Enterococcus faecalis produces extracellular superoxide and hydrogen peroxide that damages colonic epithelial cell DNA.

Authors:  Mark M Huycke; Victoria Abrams; Danny R Moore
Journal:  Carcinogenesis       Date:  2002-03       Impact factor: 4.944

9.  Probiotics have clinical, microbiologic, and immunologic efficacy in acute infectious diarrhea.

Authors:  Chien-Chang Chen; Man-Shan Kong; Ming-Wei Lai; Hsun-Chin Chao; Kuei-Wen Chang; Shih-Yen Chen; Yhu-Chering Huang; Cheng-Hsun Chiu; Wen-Chen Li; Pen-Yi Lin; Chih-Jung Chen; Tzou-Yien Li
Journal:  Pediatr Infect Dis J       Date:  2010-02       Impact factor: 2.129

10.  Infant intestinal Enterococcus faecalis down-regulates inflammatory responses in human intestinal cell lines.

Authors:  Shugui Wang; Lydia Hui Mei Ng; Wai Ling Chow; Yuan Kun Lee
Journal:  World J Gastroenterol       Date:  2008-02-21       Impact factor: 5.742

View more
  4 in total

Review 1.  The first 1000 cultured species of the human gastrointestinal microbiota.

Authors:  Mirjana Rajilić-Stojanović; Willem M de Vos
Journal:  FEMS Microbiol Rev       Date:  2014-06-27       Impact factor: 16.408

2.  In Silico and Experimental Data Claiming Safety Aspects and Beneficial Attributes of the Bacteriocinogenic Strain Enterococcus faecalis B3A-B3B.

Authors:  Alaa Al Seraih; Yanath Belguesmia; Benoit Cudennec; John Baah; Djamel Drider
Journal:  Probiotics Antimicrob Proteins       Date:  2018-09       Impact factor: 4.609

3.  Assessment of virulence potential of uncharacterized Enterococcus faecalis strains using pan genomic approach - Identification of pathogen-specific and habitat-specific genes.

Authors:  Utpal Bakshi; Munmun Sarkar; Sandip Paul; Chitra Dutta
Journal:  Sci Rep       Date:  2016-12-07       Impact factor: 4.379

4.  Enterococcus faecalis AHG0090 is a Genetically Tractable Bacterium and Produces a Secreted Peptidic Bioactive that Suppresses Nuclear Factor Kappa B Activation in Human Gut Epithelial Cells.

Authors:  Páraic Ó Cuív; Rabina Giri; Emily C Hoedt; Michael A McGuckin; Jakob Begun; Mark Morrison
Journal:  Front Immunol       Date:  2018-04-18       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.